Logo

NEUP

Neuphoria Therapeutics Inc.

NEUP

Neuphoria Therapeutics Inc. • NASDAQ
$4.52 ▲ 3.67% (+0.16)
Market Cap $8.41 M
52w High $21.40
52w Low $2.77
Dividend Yield 0%
P/E -1.12
Volume 31.99K
Outstanding Shares 1.86M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q1-2026 $0 ▲ $8.301M ▼ $-14.988M ▲ 0% ▼ $-4.41 ▲ $-14.789M ▲
Q4-2025 $-15.663M ▼ $16.768B ▲ $-378.146M ▼ 2.414K% ▲ $-6.77 ▼ $-846.807M ▼
Q3-2025 $23.874M ▲ $4.548M ▼ $17.925M ▲ 75.081% ▲ $6.55 ▲ $18.059M ▲
Q2-2025 $1.071M ▲ $7.053M ▲ $-3.139M ▼ -293.241% ▼ $-0.008 ▼ $-3.121M ▼
Q1-2025 $0 $4.917M $-1.163M 0% $-0.003 $-1.115M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q1-2026 $13.65M ▼ $27.344M ▼ $14.834M ▼ $12.51M ▼
Q4-2025 $14.211B ▲ $28.59B ▲ $9.587B ▲ $19.003B ▲
Q3-2025 $17.045M ▲ $30.713M ▲ $4.716M ▲ $25.997M ▲
Q2-2025 $4.345M ▼ $18.168M ▼ $4.42M ▼ $13.748M ▼
Q1-2025 $8.082M $22.917M $5.847M $17.07M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q1-2026 $-9.907M ▲ $-3.795M ▼ $0 $3.254M ▼ $-3.317M ▼ $-3.795M ▼
Q4-2025 $-378.146M ▼ $73.567M ▲ $0 $1.527B ▲ $14.272B ▲ $73.567M ▲
Q3-2025 $11.262M ▲ $11.453M ▲ $0 $1.163M ▲ $12.701M ▲ $11.453M ▲
Q2-2025 $-1.943M ▼ $-3.358M ▲ $0 $-107.096K ▲ $-3.746M ▲ $-3.358M ▲
Q1-2025 $-805K $-4.433M $0 $-227K $-4.522M $-4.433M

Five-Year Company Overview

Income Statement

Income Statement Neuphoria is still a classic early‑stage biotech story: almost no product revenue and a business model driven by research spending. The company runs consistent operating losses as it funds clinical trials and platform development. Those losses recently stepped up, suggesting a more active development program and possibly costs tied to the failed late‑stage trial. Overall, the income statement shows dependence on external funding rather than internally generated profits for the foreseeable future.

Balance Sheet

Balance Sheet The balance sheet has transformed from very small scale to a company with a meaningful pool of assets and cash, likely reflecting significant capital raises or partnerships. Cash now makes up a large portion of total assets, which is typical for a clinical‑stage biotech that has no products on the market yet. Debt is minimal, so the company is not heavily burdened by interest payments. Equity is clearly positive, indicating that the business is mainly financed by shareholders rather than lenders.

Cash Flow

Cash Flow Historically, Neuphoria has used cash to fund operations, as expected for a pre‑revenue drug developer. Recently, operating cash flow turned modestly positive, which may be driven by one‑off items like partnership payments or working capital shifts rather than true underlying profitability. Capital spending is negligible, so most cash movements relate to research, trials, and general corporate costs. Future cash flow will likely remain volatile and closely tied to trial spending, business development deals, and any new financing rounds.

Competitive Edge

Competitive Edge Neuphoria’s competitive edge is built around a specialized neuroscience platform focused on modulating brain receptors in a more precise way than traditional drugs. The recent failure of its lead anxiety trial, however, has weakened its perceived moat and removed one of its most immediate commercial opportunities. The remaining strength lies in its PTSD program, its broader ion channel expertise, and a notable partnership with a large pharmaceutical company that helps validate its science. Competition remains intense in CNS disorders, so execution and differentiation in upcoming studies will be crucial to maintaining relevance.

Innovation and R&D

Innovation and R&D The company is highly innovation‑driven, with its core technology targeting a key receptor involved in brain signaling using allosteric modulation—an approach aimed at achieving efficacy with fewer side effects. Its lead asset is being redirected toward PTSD after the setback in social anxiety, while earlier programs explore next‑generation modulators and other ion channel targets for cognition and neuropsychiatric conditions. A major collaboration with a global pharma partner on cognitive therapies, plus a legacy oncology out‑license, adds external validation and potential future upside from milestones. Overall, R&D is both Neuphoria’s main asset and main risk, as the value of the company hinges on clinical proof and regulatory success that are still ahead.

Summary

Neuphoria Therapeutics is a pre‑revenue, research‑focused biotech with a stronger cash position than in prior years, low debt, and an income statement dominated by R&D‑driven losses. The business model relies on external capital and partnership support while it advances a scientifically distinctive, but clinically risky, CNS pipeline. A major trial failure has raised uncertainty and forced a strategic rethink, making the success of the PTSD program and partnered assets especially important. The company’s future will be shaped by how effectively it prioritizes its pipeline, controls its cash burn, and converts its technical platform into clear, repeatable clinical wins.

NEWS

November 24, 2025 · 8:00 AM UTC

Neuphoria Therapeutics Inc. Sends Letter to Stockholders

Read more

November 11, 2025 · 7:00 AM UTC

Neuphoria Announces Initiation of Strategic Review to Maximize Stockholder Value

Read more

October 27, 2025 · 4:29 PM UTC

Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process

Read more

October 20, 2025 · 4:15 PM UTC

Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder

Read more

September 29, 2025 · 4:54 PM UTC

Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates

Read more